转移性葡萄膜黑色素瘤无进展生存与总生存基准的荟萃分析
该荟萃分析利用29项2000至2016年发表的临床试验个体患者数据,评估转移性葡萄膜黑色素瘤的PFS和OS基准。912例患者中位PFS为3.3个月(95%CI 2.9-3.6),6个月PFS率27%(95%CI 24-30);中位OS为10.2个月(95%CI 9.5-11.0),1年OS率43%(95%CI 40-47)。LDH和ALP升高是缩短PFS和OS的最显著预后因素,肝脏定向治疗与更长的PFS和OS相关。
要点
- mUM患者中位PFS 3.3个月,6个月PFS率27%
- 中位OS 10.2个月,1年OS率43%
- LDH和ALP升高是最显著的负向预后因素
核心结论
- 确定了转移性葡萄膜黑色素瘤的6个月PFS率和1年OS率基准,可考虑预后因素后用于未来试验设计和分层。
研究设计与样本
- 荟萃分析,收集29项2000至2016年发表的临床试验的个体患者变量和生存结局,进行单变量和多变量预后因素分析。
- OS数据可获取者共912例患者。
主要发现
- 中位PFS为3.3个月(95%CI 2.9-3.6),6个月PFS率为27%(95%CI 24-30)。
- 中位OS为10.2个月(95%CI 9.5-11.0),1年OS率为43%(95%CI 40-47)。
- 单变量分析显示男性、LDH升高(> vs ≤正常上限)、ALP升高和最大肝转移灶直径≥3 cm vs <3 cm与更短PFS显著相关。
- 多变量分析显示男性、LDH升高和ALP升高与更短PFS显著相关;LDH和ALP升高在单变量和多变量分析中均是与6个月PFS率最显著相关的因素。
- 单变量和多变量分析中与更短OS最显著的预后因素均为LDH升高和ALP升高;接受肝脏定向治疗的患者PFS和OS统计学显著更长。
临床怎么用
- 在解读mUM单臂试验结果和设计未来试验时,可参考6个月PFS率27%和1年OS率43%的基准。
- 预后分层应考虑LDH、ALP、性别和最大肝转移灶直径等预后因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine benchmarks of progression free survival (PFS) and overall survival (OS), we carried out a meta-analysis using individual patient level trial data. METHODS: Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016. Univariable and multivariable analysis were carried out for prognostic factors. The variability between trial arms and between therapeutic agents on PFS and OS was investigated. RESULTS: OS data were available for 912 patients. The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30). Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus <3 cm) to be substantially associated with shorter PFS. Multivariable analysis showed male sex, elevated LDH and elevated ALP were substantially associated with shorter PFS. The most substantial factors associated with 6-month PFS rate, on both univariable and multivariable analysis were elevated LDH and ALP. The median OS was 10.2 months (95% CI 9.5-11.0) and 1 year OS was 43% (95% CI 40-47). The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP. Patients treated with liver directed treatments had statistically significant longer PFS and OS. CONCLUSION: Benchmarks of 6-month PFS and 1-year OS rates were determined accounting for prognostic factors. These may be used to facilitate future trial design and stratification in mUM.
引用
- Khoja L, Atenafu EG, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019. PMID: 31150059. doi:10.1093/annonc/mdz176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。